COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Postcoital Testing of the SILCS Diaphragm

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00561613
Recruitment Status : Completed
First Posted : November 21, 2007
Last Update Posted : December 24, 2007
Information provided by:

Brief Summary:

This was a Phase I multi-center, randomized study in 40 healthy, sexually active women not at risk for pregnancy due to previous female sterilization. The male partners of the participants were consented to participate in the study. The clinician evaluating the cervical mucus for midcycle characteristics and presence of sperm was blinded as to gel used. The product tested was the SILCS diaphragm with Gynol II (spermicide) and the SILCS diaphragm with KY Jelly (lubricant). The sequence of diaphragm and gel use was determined by randomization. The study was conducted at two centers, Magee-Womens Hospital in Pittsburgh, Pennsylvania and CONRAD's Clinical Research Center at the Eastern Virginia Medical School in Norfolk, Virginia.

The study consisted of a screening visit, a baseline cycle, and up to 2 cycles of post-coital tests (PCTs) for a total of 7 visits. The first PCT was a baseline PCT, performed without the use of any product, in order to demonstrate the subject's ability to produce receptive, midcycle cervical mucus. The partner's ability to produce motile sperm capable of penetrating the cervical mucus was evaluated in this cycle. Test PCTs were carried out during the second and third menstrual cycle using either the SILCS diaphragm with N-9 or the SILCS diaphragm with lubricant. Cycles were repeated depending on the characteristics of the cervical mucus and the number of sperm found in the vaginal pool and endocervical specimens; thus, some women may undergo more than three PCTs. An additional test cycle with a modified polymer spring device was performed in a subset of participants.

Colposcopy was performed during the mucus check and post-coital test visits in all three cycles in order to document the baseline condition of the vagina and cervix pre- and post-intercourse and, in test cycles, to note the effect of product.

Vaginal samples were taken from the posterior fornix of the vagina and the cervical os at each visit during the baseline and test cycles to measure for the presence of PSA.

Condition or disease Intervention/treatment Phase
Contraceptive Device Other: SILCS and lubricant Other: SILCS and spermicide Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase I Postcoital Testing and Safety Study of the SILCS Diaphragm, Prototype VI
Study Start Date : August 2003
Actual Study Completion Date : October 2004

Arm Intervention/treatment
Placebo Comparator: 1
SILCS with K-Y Jelly
Other: SILCS and lubricant
Active Comparator: 2
SILCS with N-9
Other: SILCS and spermicide

Primary Outcome Measures :
  1. Percentage of women with any sperm in the cervical mucus, with ≥ 5 progressively motile sperm per high power field (HPF), and the average number of progressively motile sperm per HPF. [ Time Frame: Within 2-3 hours of intercourse. ]

Secondary Outcome Measures :
  1. Symptoms and signs of irritation of the external genitalia, cervix, and vagina before and after intercourse and by gel product. The handling, fit, and general acceptability of the SILCS diaphragm was assessed. [ Time Frame: Before and after intercourse ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Female Participants

    • 18-45 years old (inclusive)
    • In good general health based on medical history & physical exam
    • Previous bilateral tubal ligation or salpingectomy
    • Regular menstrual cycles of 24-35 days (inclusive)
    • Negative urine pregnancy test at admission
    • Not currently breast feeding
    • No significant gynecological abnormalities
    • Normal cervical Papanicolaou smear within 6 months preceding enrollment
    • In a stable relationship with only one sexual partner
    • Willing to undergo at least three PCTs
    • Willing to abstain from intercourse and use of vaginal products
    • Willing to use condoms from day 1 of each menstrual cycle until midcycle
  2. Male Participants

    • Age 18 years and older
    • Able and willing to provide written informed consent
    • Willing to engage in intercourse with and without condoms

Exclusion Criteria:

  1. Female Participants

    • History in subject of allergy to study products
    • Positive wet mount for Trichomonas vaginalis
    • History of any STD within 6 months of enrollment
    • Device does not appropriately fit volunteer, as determined by clinician
    • Inability to insert, position, and/or remove study device
    • Participation in another study within 30 days prior to enrollment
  2. Male Participants

    • History of allergy to study products
    • History of vasectomy
    • In the six months prior to study, diagnosed with or treated for any STI

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00561613

Layout table for location information
United States, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213
United States, Virginia
Eastern Virginia Medical School
Norfolk, Virginia, United States, 23507
Sponsors and Collaborators
Layout table for investigator information
Study Director: Jill Schwartz, MD CONRAD
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Jill Schwartz, MD/Project Leader, CONRAD Identifier: NCT00561613    
Other Study ID Numbers: A02-081
First Posted: November 21, 2007    Key Record Dates
Last Update Posted: December 24, 2007
Last Verified: December 2007
Keywords provided by CONRAD:
postcoital test
Additional relevant MeSH terms:
Layout table for MeSH terms
Spermatocidal Agents
Antispermatogenic Agents
Physiological Effects of Drugs
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents